New lupus drug CUG252 passes first safety check in small trial

NCT ID NCT05866861

Completed Disease control Sponsor: Cugene Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tested the safety of a new drug, CUG252, in 40 adults with mild-to-moderate systemic lupus erythematosus (SLE). Participants received multiple doses of the drug or a placebo by injection. The main goal was to see if the drug is safe and tolerable, and to understand how it moves through the body. The study is complete, but results are not yet available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CUG252
What this could lead to: If safe and effective, CUG252 could offer a new treatment option to control lupus symptoms.
What could go wrong: This is an early Phase 1 safety study with only 40 people. It is not designed to prove effectiveness, and many drugs fail at this stage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTOIMMUNE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune disease systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AUTOIMMUNE SLE (SYSTEMIC LUPUS) SYSTEMIC LUPUS ERYTHEMATOSUS

Contacts and locations

Locations

Site 1001

Anniston, Alabama, 36207, United States
Site 1002

Clearwater, Florida, 33765, United States
Site 1003

Duncansville, Pennsylvania, 16635, United States
Site 1004

Mesquite, Texas, 75150, United States
Site 1005

Middleburg Heights, Ohio, 44130, United States
Site 1006

Dallas, Texas, 75231, United States
Site 1007

Lawrenceville, Georgia, 30046, United States
Site 1009

Tampa, Florida, 33606, United States
Site 1010

Columbus, Ohio, 44106, United States
Site 1011

La Jolla, California, 92037, United States
Site 1012

Seattle, Washington, 98195, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.